Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regado Biosciences has appointed David Mazzo as its new president and CEO, effective immediately. Dr Mazzo replaces Regado co- founder Douglas Gooding.
Subscribe to our email newsletter
Dr Mazzo brings to Regado almost 25 years of experience in the pharmaceutical industry, most recently as president and CEO of Aeterna Zentaris.
Dr Mazzo earned a bachelor of arts degree in the honors program and a bachelor of science degree in chemistry from Villanova University. In addition, Dr Mazzo has received his master of science degree in chemistry and his PhD degree in analytical chemistry from the University of Massachusetts, Amherst.
Dennis Podlesak, chairman of the board of Regado, said: “Dr Mazzo’s senior leadership experience, his strong scientific background and commercial and regulatory expertise will be invaluable to the company as Regado advances and expands its clinical development programs.”